Inside C4 Therapeutics: New PROTAC Cemsidomide, Insider Moves and Regulatory Pathways
Insider sale at C4 Therapeutics highlights routine trading, while the new PROTAC drug cemsidomide shows strong pre‑clinical efficacy and safety—watch its Phase I/II data for clinical promise and investor insights.
3 minutes to read